Benefits of using methimazole in comparison to hydroquinone in the treatment of Melasma
DOI:
https://doi.org/10.33448/rsd-v10i16.24038Keywords:
Metimazole; Melasma; Hydroquinone.Abstract
Facial hyperchromias are pigmentary disorders caused by an increase in melanin in a specific area of the skin. Melasma is an acquired hyperchromia, clinically diagnosed, with a high rate of recurrence. Its etiopathogenesis is not fully known, including several factors that facilitate its appearance or aggravate the problem, including exposure to UV rays, genetics, pregnancy, hormonal therapies, among others. Treatment is still a challenge and for many years hydroquinone was one of the most used substances as a tyrosinase inhibitor, but it has many toxic and harmful effects on the skin and other organs. Some alternative treatments with other depigmenting agents, such as metthimazole, also for topical use, have been increasingly effective and with fewer side effects when compared to hydroquinone. This is a literature review study that consists of the existence of two objectives, which are to contextualize a problem and verify existing possibilities in the literature in the formation of the theoretical framework. Furthermore, it is a descriptive exploratory research. Articles that present melasma with the main theme and that have been published between 2009 and 2020 will be selected. Those articles published before 2009 and that have no connection with the topic will be excluded. Conclusion: the study concluded that methimazole use is safer and more effective when compared to hydroquinone, but has slower results. The importance of further research evaluating the safety and efficacy of topical methimazole use is emphasized.
References
Atefi, N., Behrangi, E., Nasiripour, S., Mehran, G., Naeji, S., Azizi, M., Hassani, P., & Azizian, Z. (2016). A double blind randomized trial of efficacy and safety of 5% methimazole versus 2% hydroquinone in patients with melasma. Journal of Skin and Stem Cell, In Press(In Press). https://doi.org/10.5812/jssc.62113
Bodo, L. F. L., da Silva Rodrigues, T., & Rabito-Melo, M. F. (2019). Eficácia e segurança de agentes despigmentantes em comparação à hidroquinona. Revista Terra & Cultura: Cadernos de Ensino e Pesquisa, 34(esp.), 154-163. http://periodicos.unifil.br/index.php/Revistateste/article/view/1019
Castro, C. C. A., Pimenta, C. L., & Dorane, I. (1997). Tratamento da hiperpigmentação: uva ursina versus hidroquinona. Comest Toiletries, 8(2), 39-43.
Chan, C. F., Lai, S.T., Guo, Y.C., & Chen, M. J. (2014). Efeitos inibitórios de novos derivados de methimazole sintético em tyrosinase de cogumelo e melananogênese. Bioorgânica & química medicinal, 22(9), 2809-2815.
Gil, A. C. (2010). Métodos e técnicas de pesquisa social (6a ed.). Atlas.
Gonchoroski, D. D., & Corrêa, G. M. (2005). Tratamento de hipercromia pós-inflamatória com diferentes formulações clareadoras. Infarma, 17(3-4), 84-8.
Kasraee, B., Hügin, A., Tran, C., Sorg, O., & Saurat, J.-H. (2004). Methimazole is an inhibitor of melanin synthesis in cultured B16 melanocytes. Journal of Investigative Dermatology, 122(5), 1338–1341. https://doi.org/10.1111/j.0022-202x.2004.22509.x
Kasraee, B., Safaee Ardekani, G. H., Parhizgar, A., Handjani, F., Omrani, G. R., Samani, M., Nikbakhsh, M., Tanideh, N., Eshraghian, A., Sorg, O., & Saurat, J. H. (2008). Safety of topical methimazole for the treatment of melasma. Skin Pharmacology and Physiology, 21(6), 300–305. https://doi.org/10.1159/000148222
Levin, C. Y., & Maibach, H. (2001). Exogenous ochronosis. American Journal of Clinical Dermatology, 2(4), 213–217. https://doi.org/10.2165/00128071-200102040-00002
Lima, A. M. S., Fontes, R. L., Mello, M. Z. L. A., & de Luna Oliveira, B. (2018). A Fotoproteção na prevenção do Câncer de Pele. Revista Saúde & Ciência Online, 7(2), 181-183. https://rsc.revistas.ufcg.edu.br/index.php/rsc/article/view/106
Malek, J., Chedraoui, A., Nikolic, D., Barouti, N., Ghosn, S., & Abbas, O. (2013). Tratamento bem sucedido de melasma resistente à hidroquinona usando mehimazole tópico. Terapia dermatológica, 26(1), 69-72.
MAZZOTTI, T. B. (2002). A metáfora percurso no debate sobre políticas educacionais no Brasil contemporâneo. Escola pública e sociedade. São Paulo: Saraiva, 124-132.
Metsavaht, L. d. (2017). Hydroquinone: Hero or villain? Surgical & Cosmetic Dermatology, 9(3). https://doi.org/10.5935/scd1984-8773.20179301
Miot, L. D.B., Miot, H. A., Silva, M. G. D., & Marques, M. E. A. (2009). Fisiopatologia do melasma. Anais brasileiros de dermatologia, 84, 623-635.
Moreira, A. M., Bravo, B. S. F., da Fonseca Amorim, A. G., Luiz, R. R., & Issa, M. C. A. (2010). Estudo duplo cego comparativo entre hidroquinona e extrato de uva-ursina no tratamento do melasma. Surgical & Cosmetic Dermatology, 2(2), 99-104.
Nicoletti, M. A., Orsine, E. M. D. A., Duarte, A. C. N., & Buono, G. A. (2002). Hipercromias: aspectos gerais e uso de despigmentantes cutâneos. Cosmetics & Toiletries (Edição em Português), 14.
Nogueira, d. S. E., & Costa, L. M. O. (2019). Efeitos do pycnogenol® (extrato da casca de pinus pinastes) como antioxidante e clareador - revisão de literatura. Revista Saúde em Foco, (11).
Nordlund, J. J., Grimes, P. E., & Ortonne, J. P. (2006). A segurança da hidroquinona. Journal of the European Academy of Dermatology and Venereology, 20(7), 781-787
Prignano, F., Ortonne, J. P., Buggiani, G., & Lotti, T. (2007). Therapeutical approaches in melasma. Dermatologic clinics, 25(3), 337-342.
Souza, L. C. D., Amurim, N. P., & Grignolli, L. C. M. E. (2018). O uso associado do ácido kójico e ácido glicólico como alternativa à hidroquinona no tratamento de melasma. Revista Científica Multidisciplinar Núcleo do Conhecimento, 1(2), 49-68.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2021 Fernanda Novaes Fernandes; Gisllainy Aguiar Vieira; Jeane Rocha Santos
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
1) Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
2) Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
3) Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
